<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00351403</url>
  </required_header>
  <id_info>
    <org_study_id>INDIV-2</org_study_id>
    <secondary_id>2006-000358-38</secondary_id>
    <nct_id>NCT00351403</nct_id>
  </id_info>
  <brief_title>Individually Adapted Therapy Duration for the Treatment of Chronic Hepatitis C Genotype 1 Infection</brief_title>
  <official_title>Individually Adapted Therapy Duration From 24 to 72 Weeks for the Treatment of a Chronic Hepatitis C Genotype 1 Infection With Peginterferon Alfa-2b Plus Ribavirin in Dependence of the Initial Concentration and the Decline of the HCV RNA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FGK Clinical Research GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>FGK Clinical Research GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with chronic hepatitis C genotype 1 virus infection are usually treated with
      Interferon alfa plus Ribavirin over 48 weeks. For some patients this might be too long, for
      others too short. An individually adapted therapy length from 24 to 72 weeks will be
      determined in dependence of the initial virus load and the time to HCV RNA negativity.

      The primary objective is to compare the cumulative rate of the sustained viral response (SVR)
      of the patients with the individually adapted therapy duration to the SVR rates of a historic
      patient collective under the 48 week standard therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Further objectives of this trial are:

      To record the tolerance of the therapy with Peginterferon alfa-2b plus Ribavirin over 72
      weeks inclusive the adverse reactions and the withdrawal rates.

      To evaluate the biochemical response to the treatment (ALT values during and after the
      therapy) in comparison to the virological response to the treatment.

      To evaluate the validity of the withdrawal rules of this trial at week 12 and 24 in
      comparison to the 2-log-rule and a qualitative detection of the HCV RNA at week 24 with a
      detection limit of 50 IU/ml.

      To evaluate the impact of the HCV RNA concentration before the therapy, and the HCV kinetic
      during the therapy on the response to the treatment in the different groups.

      To evaluate the impact of the serum concentration of Ribavirin on anaemia and the virological
      therapy response, as well as the dependence of the serum concentration of Ribavirin on the
      creatinine clearance in comparison to the body weight.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained viral response (HCV RNA negativity 24 weeks after end of treatment)</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Individualized therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lengh of therapy depends on time point when no HCV RNA is detectable in blood with Versant HCV Qualitative assay.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Historical control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>48 week standard therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Rebetol 200 mg: applied as hard capsule</description>
    <arm_group_label>Individualized therapy</arm_group_label>
    <arm_group_label>Historical control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa 2b</intervention_name>
    <description>PegIntron (50/80/100/120/150 microgram): applied by injection</description>
    <arm_group_label>Individualized therapy</arm_group_label>
    <arm_group_label>Historical control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a chronic HCV infection (HCV antibodies and HCV RNA positive)

          -  Presence of a HCV genotype 1 infection

          -  Presence of a compensated liver disease satisfying following hematological and
             biochemical minimum criteria: - Hemoglobin value &gt;= 13 g/dl in men, &gt;= 12 g/dl in
             women - Leukocytes &gt;= 3.000/mm3 or neutrophile granulocytes &gt; 1.500/mm3 - Thrombocytes
             &gt; 80.000/mm3

          -  Total bilirubin in the normal range

          -  Albumin in the normal range

          -  Serum creatinine in the normal range THS in the normal range

          -  Exclusion of an autoimmune hepatitis

          -  Alpha-Fetoprotein in the normal range

          -  Negative HIV test

          -  Negativity of Hepatitis B surface antigens (Hbs-Ag)

          -  Normal or elevated ALT/GTP values at screening

          -  At known diabetes mellitus or hypertension an ophthalmologic examination must be
             performed

          -  Liver biopsy within the last 12 months must confirm the diagnoses of a chronic
             hepatitis

          -  A confirmation must be given that sexually active patients practice a save method of
             contraception during the therapy and 6 (women) to 7 (men) months after the therapy

        Exclusion Criteria:

          -  Age &lt; 18 years, &gt; 70 years

          -  Previous treatment of hepatitis c with (Peg)Interferon alfa or (Peg)Interferon
             alfa/Ribavirin

          -  Patients with organ transplantations other than cornea or hair

          -  Infection with HCV genotype 2,3,4,5 or 6

          -  Pregnant or nursing women

          -  Any other reason for the liver disease than chronic hepatitis C

          -  Suspected hypersensitivity to Interferon, Peginterferon or Ribavirin

          -  Participation in a clinical trial or treatment with an investigational product 30 days
             before inclusion in this study

          -  Patients with any kind of hemoglobinopathy

          -  Documented liver disease in advanced state Liver cirrhosis Child B and C

          -  Each known and existing clinical conditions that might challenge the participation or
             completion of this clinical trial as depressions, psychosis, severe psychiatric
             diseases, suicide ideations CNS traumata or cramps which need medicamentous treatment

          -  Relevant cardiovascular dysfunctions in the last 6 months or patients with clinically
             relevant changes in the ECG

          -  Insufficiently adjusted diabetes mellitus

          -  Severe chronic lung diseases (as e.g. COPD)

          -  Immunologic diseases or autoimmune-diseases or any other disease which demand a
             longtime treatment with corticosteroids during this clinical trial

          -  Clinically relevant gout

          -  Abuse of drugs, alcohol or pharmaceuticals

          -  Patient with clinically relevant changes of the retina

          -  Missing ability or willingness to understand the purpose of this study or to give a
             written consent for participating in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Sarrazin, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Saarland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91056</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Großhadern</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technische Universität München</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Würzburg</name>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.W.-Goethe-Universität</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Innere Medizin</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Josef-Hospital</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis</name>
      <address>
        <city>Dusseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40237</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitäts-Klinik Essen</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität zu Köln</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein.Westfalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum der J. Gutenberg Universität</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg / Saar</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian-Albrechts-Universität zu Kiel</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hepatologische Schwerpunktpraxis</name>
      <address>
        <city>Berlin</city>
        <zip>10969</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité, Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2006</study_first_submitted>
  <study_first_submitted_qc>July 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2006</study_first_posted>
  <last_update_submitted>February 5, 2010</last_update_submitted>
  <last_update_submitted_qc>February 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Christoph Sarrazin, MD, PhD</name_title>
    <organization>Universitätsklinikum des Saarlandes</organization>
  </responsible_party>
  <keyword>Chronic HCV infection</keyword>
  <keyword>Genotype 1</keyword>
  <keyword>Individually adapted therapy</keyword>
  <keyword>Peginterferon alfa-2b</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Sustained viral response (SVR)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

